News

OxyDial recently had the privilege to attend the Society for the Advancement of Patient Blood Management (SABM) Annual Meeting in Minneapolis, where we were warmly welcomed as a new member …

We’ll be taking the stage in the Healthcare Track, sharing our vision for precision hemoglobin and blood analysis with investors, industry leaders, and innovators shaping the future of healthcare. This …

Over the weekend, OxyDial stood beside an incredible community – people living with sickle cell disease, caregivers, advocates, and partners – united under one purpose: to raise awareness, share real …

Last week, we had the privilege of attending the Society for the Advancement of Patient Blood Management, Inc. (SABM) Annual Meeting. We were deeply inspired by the presentations from leading …

Fulcrum Therapeutics presented compelling Phase 1B data for its lead candidate, Posiradir, at the H.C. Wainwright Conference, underscoring its potential as a novel oral treatment for sickle cell disease (SCD). …

Sanofi has achieved a significant milestone with the FDA approval of Wayrilz (rilzabrutinib) for immune thrombocytopenia (ITP), marking it as the first Bruton’s tyrosine kinase (BTK) inhibitor approved for this …

Oryzon Genomics SA has received approval from the European Medicines Agency to initiate its Phase 1b RESTORE trial for iadademstat in patients with sickle cell disease (SCD). The trial will …

AstraZeneca has cleared a major hurdle with China’s approval of its $160 million acquisition of FibroGen, Inc.’s China unit. This strategic move grants AstraZeneca full regional rights to the anemia …

FibroGen, Inc. and Astellas Pharma have reached a milestone with the FDA’s green light to advance roxadustat into Phase 3 trials for anemia in lower-risk myelodysplastic syndromes (LR-MDS). This oral …